Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19

Oct 19, 2026 · 06:02 AM ET· updated 53m ago

Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have

Share
Why It Matters

Belite Bio got approved to trade on Nasdaq starting October 19. When a new company starts trading, watch how many people buy and sell to learn if they believe in it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
BLTE142.78
-9.84 (-6.45%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.